0.35
-0.0072(-2.00%)
Currency In USD
| Previous Close | 0.36 |
| Open | 0.36 |
| Day High | 0.37 |
| Day Low | 0.35 |
| 52-Week High | 10.62 |
| 52-Week Low | 0.3 |
| Volume | 1.77M |
| Average Volume | 2.27M |
| Market Cap | 50.02M |
| PE | -1.47 |
| EPS | -0.24 |
| Moving Average 50 Days | 0.42 |
| Moving Average 200 Days | 3.34 |
| Change | -0.01 |
If you invested $1000 in Applied Therapeutics, Inc. (APLT) since IPO date, it would be worth $37.59 as of June 01, 2025 at a share price of $0.353. Whereas If you bought $1000 worth of Applied Therapeutics, Inc. (APLT) shares 5 years ago, it would be worth $7.61 as of June 01, 2025 at a share price of $0.353.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
GlobeNewswire Inc.
May 18, 2025 11:28 AM GMT
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
GlobeNewswire Inc.
May 09, 2025 9:00 PM GMT
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extensionNEW YORK, May 09, 2025 (GLOBE NEWSWIRE) --
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
GlobeNewswire Inc.
Mar 31, 2025 11:10 AM GMT
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of